Maite Verreault
Overview
Explore the profile of Maite Verreault including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
931
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Verreault M, Vilchis I, Rosenberg S, Lemaire N, Schmitt C, Guehennec J, et al.
Clin Transl Med
. 2022 Jul;
12(7):e939.
PMID: 35808822
Objective: New therapeutic approaches are needed to improve the prognosis of glioblastoma (GBM) patients. Methods: With the objective of identifying alternative oncogenic mechanisms to abnormally activated epidermal growth factor receptor...
12.
Ahmed M, Hernandez-Verdin I, Bielle F, Verreault M, Lerond J, Alentorn A, et al.
Can J Neurol Sci
. 2022 Jan;
50(2):234-242.
PMID: 35022089
Background: Strategies to modulate the tumor microenvironment (TME) have opened new therapeutic avenues with dramatic yet heterogeneous intertumoral efficacy in multiple cancers, including glioblastomas (GBMs). Therefore, investigating molecular actors of...
13.
Vessieres A, Quissac E, Lemaire N, Alentorn A, Domeracka P, Pigeon P, et al.
Int J Mol Sci
. 2021 Oct;
22(19).
PMID: 34638742
Glioblastoma (GBM) is the most frequent and deadliest primary brain cancer in adults, justifying the search for new treatments. Some members of the iron-based ferrocifen family have demonstrated a high...
14.
Juric V, Hudson L, Fay J, Richards C, Jahns H, Verreault M, et al.
Cell Death Dis
. 2021 Aug;
12(8):763.
PMID: 34344865
Activation of cyclin-dependent kinases (CDKs) contributes to the uncontrolled proliferation of tumour cells. Genomic alterations that lead to the constitutive activation or overexpression of CDKs can support tumourigenesis including glioblastoma...
15.
Geraldo L, Xu Y, Jacob L, Pibouin-Fragner L, Rao R, Maissa N, et al.
J Clin Invest
. 2021 Jun;
131(16).
PMID: 34181595
SLIT2 is a secreted polypeptide that guides migration of cells expressing Roundabout 1 and 2 (ROBO1 and ROBO2) receptors. Herein, we investigated SLIT2/ROBO signaling effects in gliomas. In patients with...
16.
Boccellato C, Kolbe E, Peters N, Juric V, Fullstone G, Verreault M, et al.
Cell Death Dis
. 2021 Jun;
12(7):647.
PMID: 34168123
Due to the absence of curative treatments for glioblastoma (GBM), we assessed the efficacy of single and combination treatments with a translationally relevant 2nd generation TRAIL-receptor agonist (IZI1551) and the...
17.
Lasri A, Juric V, Verreault M, Bielle F, Idbaih A, Kel A, et al.
R Soc Open Sci
. 2020 Sep;
7(7):191243.
PMID: 32874597
Glioblastoma (GBM) is the most aggressive malignant primary brain tumour with a median overall survival of 15 months. To treat GBM, patients currently undergo a surgical resection followed by exposure...
18.
Touat M, Li Y, Boynton A, Spurr L, Iorgulescu J, Bohrson C, et al.
Nature
. 2020 Apr;
580(7804):517-523.
PMID: 32322066
A high tumour mutational burden (hypermutation) is observed in some gliomas; however, the mechanisms by which hypermutation develops and whether it predicts the response to immunotherapy are poorly understood. Here...
19.
Jubran M, Rubinstein A, Cojocari I, Adejumobi I, Mogilevsky M, Tibi S, et al.
Oncogenesis
. 2020 Feb;
9(2):11.
PMID: 32024816
Glioblastoma (GBM) is a highly infiltrative brain cancer, which is thus difficult to operate. GBM cells frequently harbor Epidermal Growth Factor Receptor amplification (EGFRwt) and/or activating mutation (EGFRvIII), generating at...
20.
Drean A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, et al.
J Neurooncol
. 2019 Jun;
144(1):33-41.
PMID: 31197598
Introduction: Glioblastoma (GBM) is the most common and aggressive primary brain cancer in adults. Few cytotoxic chemotherapies have been shown to be effective against GBM, due in part to the...